UroGen develops novel therapies with a focus on uro-oncology. Its lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, and are being developed under the 505(b)2 regulatory pathway. These products are formulated using the Company’s proprietary hydrogel technology,
RTGel, which provides for sustained release of an active drug.